Susanne Posel
Activist Post

FDA Approves Meningitis Vaccine After Big Pharma Conducts Human Experiments

The Food and Drug Administration (FDA) has given GlaxoSmithKilne (GSK) their approval of the MenHibrix vaccine(MHV), which is meant for infants between the ages of 6 weeks to 18 months. This vaccine is a dangerous mixture of the meningococcal disease and Hib disease.

MHV will be manufactured in Rixensart, a Belgium-based arm of GSK Biologicals.

In 2010 and 2011, the FDA rejected MHV. GSK claims that they have “resolved” the FDA’s concerns about the necessity, potency and efficiency of MHV. This simply accepted GSK’s word that they have taken care of the vaccine’s issues. The FDA does not require more proof than that.

In fact, the FDA’s standard practice is to regulate drugs after they have been approved, rather than just making sure they are safe before releasing them out to the public.

In 2008, the FDA admitted that there is no regulatory checking of safety of trials. The FDA relied solely on the data provided them from the drug makers themselves.

Furthermore, the FDA does not check or regulate cosmetics prior to their release to the markets for the public to purchase. They leave the safety responsibility to the cosmetic corporations to essentially regulate themselves.

According to the Centers for Disease Control and Prevention (CDC), infants are most at risk for contracting bacterial meningitis, which is an infection that attacks the thin lining surrounding the brain and spinal cord.

Last month, the CDC was involved in a propaganda campaign to coerce Americans to start receiving immunizations after the recent decline reported by doctors across the country.

Karen Midthum, director of the center for biologics at the FDA stated that:

With today’s approval of Menhibrix, there is now a combination vaccine that can be used to prevent potentially life-threatening Hib disease and two types of meningococcal disease in children. It is the first meningococcal vaccine that can be given starting as young as six weeks of age.

The MHV will be administered as a four-dose vaccine that the CDC recommended is added to infant’s immunizations schedule.

Dr. Leo Friedland, vice president of clinical and medical affairs at GSK North American division says:

(Meningitis) is one of those diseases that although not common, when it occurs it’s absolutely devastating and horrible. It presents to the doctor when a child just looks ill, and within 18 to 24 hours, they’re on the deathbed in the hospital. . . To be able to have a vaccine to prevent meningitis is really a great day.

The MHV targets only the C and Y strains of meningococcal bacteria and the Hib bacteria (a.k.a. Haemophilus influenzae type b).

• GSK says there is no vaccine in the US to treat the B strain of the meningococcal bacteria.
• GSK is planning on administering 1.1 billion doses of MHV to 173 countries in developed and developing countries.
• GSK maintains that MHV was evaluated on 7,500 infants and toddlers in the U.S., Mexico and Austria.

Read Full Article

FOLLOW SET YOU FREE NEWS: